Companies · Biotechnology

Iterative Scopes, Inc.

Cambridge · Biotechnology

Diligence memoA one-page analyst read on Iterative Scopes, Inc. — recommendation, valuation, rhythm, risks.
$172.1M
Total raised · real
2
Rounds
4.4×
Latest step-up
Top 5%
Sector rank · raised
Series D+
Latest stage · inferred · Mon Dec 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Iterative Scopes, Inc. looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.85× the median modeled value of Series D+ Biotechnology companies in 2019–2021 (58 peers) — value vs value, same stage and era.
  • Within the normal band (85% of peer median) for its niche.
Dormant
  • Last raise 4.6 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Iterative Scopes, Inc. is one of 4291 Biotechnology companies tracked from Cambridge. By capital raised it ranks among the largest (ahead of 96% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
32
Investors (latest)
2017
Year incorporated
2021-12-06
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries B · 2021-07-23 Raised $32M (real) Modeled valuation $807M (est)$32M$807MSeries B2021Series D+ · 2021-12-06 Raised $140M (real) Modeled valuation $3.6B (est)$140M$3.6BSeries D+2021+$140MCumulative $172M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$32.1M · 2021
Series D+$140.0M · 2021no Series C on file

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$3.6B
Base estimate est.
$634.7M
Conservative case
$6.7B
Upside case
$1.2B
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $807.2M · 2021-07-232021Series D+ · modeled $3.6B · 2021-12-062021
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
54% low · 75% high
1.39×/yr
Annual markup
1.56×/yr upside case
4.6 yr
Elapsed time used
4.6 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
4 mo
Avg between rounds
$462.1M/yr
Capital velocity
4.9 yr
On record since
2021
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 24× above median
This company$172.1M
Sector median$7.2M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 1.2× above median
This company$140.0M
Sector median$120.0M
Modeled value — vs sector median (estimate, all stages) 56× above median
This company$3.6B
Sector median$64.2M

Raised more than 96% of sector peers (real $). Modeled value above 98% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #45 of 58.

This companyCohort peer
$1.0B$10.0B$100.0B$100.0M$1.0BCapital raised (log)Sarepta Therapeutics, Inc. · Series D+ Raised $430.5M · modeled $16.5B (est)Asklepios BioPharmaceutical, Inc. · Series D+ Raised $199.7M · modeled $8.2B (est)Affinivax, Inc. · Series D+ Raised $233.0M · modeled $7.8B (est)Sonoma Biotherapeutics, Inc. · Series D+ Raised $265.0M · modeled $7.7B (est)Instil Bio, Inc. · Series D+ Raised $381.2M · modeled $6.5B (est)Umoja Biopharma, Inc. · Series D+ Raised $210.0M · modeled $6.3B (est)NiKang Therapeutics, Inc. · Series D+ Raised $200.0M · modeled $6.2B (est)Insitro, Inc. · Series D+ Raised $143.2M · modeled $5.9B (est)Arbor Biotechnologies, Inc. · Series D+ Raised $230.6M · modeled $5.7B (est)VelosBio Inc. · Series D+ Raised $210.5M · modeled $5.6B (est)Erasca, Inc. · Series D+ Raised $183.7M · modeled $5.2B (est)Allovir, Inc. · Series D+ Raised $151.3M · modeled $5.0B (est)Iterative Scopes, Inc. (this company) Raised $172.1M · modeled $3.6B (est)Iterative Scopes, Inc.
CompanyStageRaised · realValue · estvs peer med.
Sarepta Therapeutics, Inc.Series D+$430.5M$16.5B3.92×
Asklepios BioPharmaceutical, Inc.Series D+$199.7M$8.2B1.96×
Affinivax, Inc.Series D+$233.0M$7.8B1.86×
Sonoma Biotherapeutics, Inc.Series D+$265.0M$7.7B1.82×
Instil Bio, Inc.Series D+$381.2M$6.5B1.54×
Umoja Biopharma, Inc.Series D+$210.0M$6.3B1.51×
NiKang Therapeutics, Inc.Series D+$200.0M$6.2B1.46×
Insitro, Inc.Series D+$143.2M$5.9B1.40×
Arbor Biotechnologies, Inc.Series D+$230.6M$5.7B1.36×
VelosBio Inc.Series D+$210.5M$5.6B1.33×
Erasca, Inc.Series D+$183.7M$5.2B1.23×
Allovir, Inc.Series D+$151.3M$5.0B1.19×
Iterative Scopes, Inc. this companySeries D+$172.1M$3.6B0.85×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$32.1M2021-07-23$178.1M$807.2M90%
Series D+$140.0M2021-12-06$1.2B$3.6B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$32.1M2021-07-23
    • First recorded raise — entered as Series B.
    • 31 investors on this round.
  2. Series D+$140.0M2021-12-06
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 4.4× larger than the prior — scaling up.
    • 32 investors on this round.
Intelligence
2022 ~Q2
Modeled next raise · ~4mo cadence
$420.0M
Modeled next size est.range $273.0M$672.0M
4.4×
Last step-up
$462.1M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
PETER MORAN8 other2021-07
Lonne Jaffe7 other2021-12
Charles Cooney3 other2021-07
Nan Li3 other2021-07
Paul Huber2 other2021-12
Jonathan Ng2021-07
Registry & provenance

Iterative Scopes, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1874104
SEC CIK
2017
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Alzheon, Inc.BiotechnologySeries D+$172.5M$1.6Bsame sector · same stage
Nutcracker Therapeutics, Inc.BiotechnologySeries D+$172.5M$4.1Bsame sector · same stage
2seventy bio, Inc.BiotechnologySeries D+$170.0M$4.0Bsame sector · same stage
Ensoma, Inc.BiotechnologySeries D+$169.6M$2.3Bsame sector · same stage
Aktis Oncology, Inc.BiotechnologySeries D+$175.0M$1.8Bsame sector · same stage
Atea Pharmaceuticals, Inc.BiotechnologySeries D+$175.9M$4.4Bsame sector · same stage
Sangart IncBiotechnologySeries D+$165.9M$4.2Bsame sector · same stage
Camp4 Therapeutics CorpBiotechnologySeries D+$179.6M$2.2Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Heligenics, Inc.BiotechnologySeed$11.8M86%
Mosaic Biosciences, Inc.BiotechnologySeries A$176.1M86%
IGM Biosciences, Inc.BiotechnologySeries B$247.9M86%
Portal Biotechnologies, Inc.BiotechnologySeries A$49.5M86%
AtlasXomics Inc.BiotechnologySeed$76.4M86%
Algorithm Sciences, Inc.BiotechnologySeed$1.9M85%
BioMedomics, Inc.BiotechnologyPre-Seed$29.3M85%
Shoreline Biosciences, Inc.BiotechnologySeries D+$3.7B85%
Frequently asked
How much funding has Iterative Scopes, Inc. raised?
Iterative Scopes, Inc. has raised approximately $172.1M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Iterative Scopes, Inc.'s estimated valuation?
Provath's modeled valuation for Iterative Scopes, Inc. is approximately $3.6B (modeled range $634.7M–$6.7B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Iterative Scopes, Inc. at?
Iterative Scopes, Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Mon Dec 06.
What does Iterative Scopes, Inc. do and where is it based?
Iterative Scopes, Inc. operates in the Biotechnology sector, based in Cambridge.
Explore related

See where Iterative Scopes, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Iterative Scopes, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.